GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (OTCPK:NRXBF) » Definitions » Goodwill-to-Asset

NRXBF (NurExone Biologic) Goodwill-to-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NurExone Biologic Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. NurExone Biologic's Goodwill for the quarter that ended in Dec. 2024 was $0.00 Mil. NurExone Biologic's Total Assets for the quarter that ended in Dec. 2024 was $2.44 Mil.


NurExone Biologic Goodwill-to-Asset Historical Data

The historical data trend for NurExone Biologic's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Goodwill-to-Asset Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Goodwill-to-Asset
- - - -

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NurExone Biologic's Goodwill-to-Asset

For the Biotechnology subindustry, NurExone Biologic's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NurExone Biologic's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Goodwill-to-Asset falls into.


;
;

NurExone Biologic Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

NurExone Biologic's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Goodwill to Asset (A: Dec. 2024 )=Goodwill/Total Assets
=0/2.441
=

NurExone Biologic's Goodwill to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Goodwill to Asset (Q: Dec. 2024 )=Goodwill/Total Assets
=0/2.441
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NurExone Biologic  (OTCPK:NRXBF) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


NurExone Biologic Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.